The World Health Organization (WHO) has elevated the public health risk associated with the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC) from “high” to “very high.” This alarming shift comes as nearly 750 suspected cases have been reported, alongside a tragic toll of 177 suspected fatalities. This surge in cases has raised concerns not just within DRC, but across the African continent.
Rising Case Numbers and Regional Impact
As of the latest update, DRC has confirmed 82 cases of the Bundibugyo strain of Ebola, leading to seven confirmed deaths. The situation has prompted the WHO to assess the risk at the national level as “very high,” while maintaining a “high” status for the broader African region. In neighbouring Uganda, two cases of the Bundibugyo strain have been reported, linked to individuals who had recently travelled from DRC. Fortunately, Dr Tedros Adhanom Ghebreyesus, the Director-General of the WHO, characterised Uganda’s situation as “stable.”
Ebola, a rare but lethal viral disease, typically infects animals such as fruit bats before making the leap to humans. The Bundibugyo variant, while less deadly than other strains, poses unique challenges due to the limited availability of preventive measures and treatments. The recent rise in cases has intensified fears in affected communities, with locals expressing their anxiety over the rapid spread of the virus.
Vaccine Development Efforts
In response to the outbreak, researchers at Oxford University are making strides towards developing a new vaccine, which could enter clinical trials within the next two to three months. This vaccine builds upon the technology used for the AstraZeneca Covid-19 vaccine, although its efficacy remains uncertain until further testing is conducted. Animal trials are currently underway, and the Serum Institute of India stands ready to mass-produce the vaccine once Oxford can provide the necessary materials.
In addition to this initiative, another experimental Bundibugyo vaccine is being developed, although it may take six to nine months before it is ready for human testing. Dr Vasee Moorthy, a WHO adviser on research and development, has identified this vaccine as potentially the most promising option available, comparable to Ervebo, which is already in use for the more prevalent Zaire strain of Ebola.
Community Response and Challenges
The outbreak has not only posed a significant health risk but has also sparked unrest in the affected regions. Following the refusal of health workers to release the body of an Ebola victim due to contamination risks, angry relatives set fire to a hospital in
